Jun 2026 (Q3 FY26) — Aug 13, 2026
NeuroOne Q3 FY26 — Strong Revenue Growth, ISO Certification, and Pipeline Progress
Read the full callNeuroOne (NMTC) earnings
- Jun 2026
- Jun 2026 (Q3 FY26)
- Sep 2025
NeuroOne earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 2.0 | +16.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -122.9 | −11.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -2.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1 +4.17% · +$0.04
Performance −79.8% 1Y
1Y: $4.95 on 17 Oct 2025 → $1. High $5.88 (6 Jan 2026), low $0.96 (16 Oct 2026).
- Previous close
- $0.96
- 52-week range
- $0.96 – $5.88
- One year
- −79.92%
Overview
- Symbol
- NMTC
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
NeuroOne earnings calls (NMTC)
Financials
What the filings say
Net profit, year on year: −34% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 3 | 1 | 2 | 3 | 3 | 2 | 2 |
| Operating profit | -3 | 2 | -3 | -2 | -1 | -2 | -2 | -2 |
| Operating margin | −1034.5% | 52.3% | −193.3% | −111.2% | −50.0% | −59.0% | −128.7% | −122.9% |
| Profit before tax | -3 | 2 | -2 | -2 | -2 | -1 | -2 | -2 |
| Net profit | -3 | 2 | -2 | -2 | -2 | -1 | -2 | -2 |
| EPS ($ per share) | — | 0.06 | -0.44 | -0.19 | — | -0.03 | -0.28 | -0.23 |
| Line item | Dec 2017 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -5 | -17 | -31 | -41 | -51 | -63 | -75 | -79 |
| Total liabilities | 5 | 2 | 3 | 1 | 3 | 2 | 5 | 4 |
| Fixed assets | — | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Investments | — | — | — | — | 3 | — | — | — |
| Total assets | 0 | 1 | 5 | 8 | 13 | 8 | 5 | 11 |
| Line item | Dec 2017 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -2 | -5 | -3 | -9 | -8 | -13 | -11 | -3 |
| Cash from investing | -0 | -0 | -0 | -0 | -3 | 3 | -0 | -0 |
| Cash from financing | 2 | 6 | 7 | 12 | 12 | 7 | 7 | 8 |
| Net cash flow | — | — | 4 | 3 | — | — | — | — |
| Capital expenditure | — | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Free cash flow | — | -5 | -4 | -9 | -8 | -13 | -11 | -3 |
Insider filings
22 filings between Dec 18, 2025 and Aug 27, 2026.
Open market
decisions to buy or sellPurchases
$737.4K
2 purchases by 1 insider
Sales
$54.9K
6 sales by 1 insider
Compensation
not trading decisions- 5
- Award — granted as compensation
- 9
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Wambeke David J. | $737.4K | — | Aug 27, 2026 |
| Christianson Mark | — | $54.9K | Jun 30, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 27, 2026 | Wambeke David J. Chief Business Officer | Purchase | 33,333 | $67.0K |
| Jun 30, 2026 | Christianson Mark Market Development Director | Sale | 10,000 | $31.8K |
| Apr 3, 2026 | MATHIESEN JEFFREY S Director | Award | 41,929 | $0 |
| Apr 3, 2026 | Andrle Edward Director | Award | 41,929 | $0 |
| Apr 3, 2026 | Mills Jason Richard Director | Award | 41,929 | $0 |
| Apr 3, 2026 | BUCKMAN PAUL Director | Award | 41,929 | $0 |
| Mar 31, 2026 | Rosa David A CEO and President | Tax withheld | 2,458 | $1.9K |
| Mar 31, 2026 | Christianson Mark Business Development Director | Tax withheld | 253 | $197 |
| Mar 31, 2026 | Mertens Steve Chief Technology Officer | Tax withheld | 906 | $704 |
| Mar 30, 2026 | Christianson Mark Business Development Director | Sale | 15,363 | $11.4K |
| Mar 13, 2026 | Christianson Mark Business Development Director | Sale | 100 | $80 |
| Mar 12, 2026 | Christianson Mark Business Development Director | Sale | 817 | $654 |
| Mar 11, 2026 | Christianson Mark Business Development Director | Sale | 2,109 | $1.7K |
| Mar 10, 2026 | Christianson Mark Business Development Director | Sale | 11,611 | $9.3K |
| Mar 1, 2026 | Wambeke David J. Chief Business Officer | Purchase | 1,000,000 | $670.4K |
| Feb 18, 2026 | Christianson Mark Business Development Director | Tax withheld | 1,812 | $1.2K |
| Feb 18, 2026 | Mertens Steve Chief Technology Officer | Tax withheld | 7,376 | $5.0K |
| Feb 18, 2026 | Rosa David A CEO and President | Tax withheld | 71,325 | $48.5K |
| Dec 31, 2025 | Christianson Mark Business Development Director | Tax withheld | 253 | $192 |
| Dec 31, 2025 | Mertens Steve Chief Technology Officer | Tax withheld | 906 | $687 |
| Dec 31, 2025 | Rosa David A CEO and President | Tax withheld | 2,458 | $1.9K |
| Dec 18, 2025 | Mills Jason Richard Director | Award | 7,758 | $0 |
| Sep 30, 2025 | Christianson Mark Business Development Director | Tax withheld | 253 | $225 |
| Sep 30, 2025 | Mertens Steve Chief Technology Officer | Tax withheld | 906 | $805 |
| Sep 30, 2025 | Rosa David A CEO and President | Tax withheld | 2,458 | $2.2K |
| Sep 5, 2025 | Christianson Mark Business Development Director | Sale | 30,000 | $22.2K |
| Jun 30, 2025 | Rosa David A CEO and President | Tax withheld | 2,458 | $1.7K |
| Jun 30, 2025 | Mertens Steve Chief Technology Officer | Tax withheld | 906 | $614 |
| Jun 30, 2025 | Christianson Mark Business Development Director | Tax withheld | 253 | $172 |
| Jun 4, 2025 | Christianson Mark Business Development Director | Sale | 10,000 | $5.8K |
| May 22, 2025 | Christianson Mark Business Development Director | Sale | 8,967 | $5.6K |
| May 21, 2025 | Christianson Mark Business Development Director | Sale | 14 | $9 |
| May 20, 2025 | Christianson Mark Business Development Director | Sale | 3,013 | $2.0K |
| May 19, 2025 | Christianson Mark Business Development Director | Sale | 8,006 | $5.3K |
| Apr 4, 2025 | McClurg Ronald W. Chief Financial Officer | Purchase | 200,000 | $100.0K |
| Apr 4, 2025 | Rosa David A CEO and President | Purchase | 100,000 | $50.0K |
| Mar 31, 2025 | Mertens Steve Chief Technology Officer | Tax withheld | 906 | $770 |
| Mar 31, 2025 | Rosa David A CEO and President | Tax withheld | 2,458 | $2.1K |
| Feb 18, 2025 | Christianson Mark Business Development Director | Tax withheld | 1,812 | $2.1K |
| Feb 18, 2025 | Mertens Steve Chief Technology Officer | Tax withheld | 7,376 | $8.6K |
| Feb 18, 2025 | Rosa David A CEO and President | Tax withheld | 71,325 | $82.7K |
| Feb 14, 2025 | BUCKMAN PAUL Director | Award | 27,778 | $0 |
| Feb 14, 2025 | Andrle Edward Director | Award | 27,778 | $0 |
| Feb 14, 2025 | MATHIESEN JEFFREY S Director | Award | 27,778 | $0 |
| Jan 31, 2025 | Christianson Mark Business Development Director | Tax withheld | 90 | $103 |
| Jan 31, 2025 | Mertens Steve Chief Technology Officer | Tax withheld | 252 | $290 |
| Jan 31, 2025 | Rosa David A CEO and President | Tax withheld | 2,239 | $2.6K |
| Dec 31, 2024 | Christianson Mark Business Development Director | Tax withheld | 343 | $283 |
| Dec 31, 2024 | Mertens Steve Chief Technology Officer | Tax withheld | 1,158 | $957 |
| Dec 31, 2024 | Rosa David A CEO and President | Tax withheld | 4,697 | $3.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for NEUROONE MEDICAL TECHNOLOGIES Corp
Free account. Everything above stays public.
Write why you follow NEUROONE MEDICAL TECHNOLOGIES Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading